Zhonghua nei ke za zhi · 2012
[The value of ankylosing spondylitis disease activity score in evaluating disease activity of ankylosing spondylitis].
Аннотация на английскомСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
DU Xu-na, Li Yan, Zhang Sheng-li, Zhu Jian, Huang Feng
Аннотация
OBJECTIVE: To investigate the value of ankylosing spondylitis (AS) disease activity score (ASDAS) and the Bath AS disease activity index (BASDAI) in evaluating disease activity in AS.
METHODS: ASDAS and BASDAI were used to evaluate disease activity in patients with AS, taking the patients' global scores, physician global scores and treatment decision as the "gold standard" for disease activity. According to the "gold standard", the patients were divided into low and high disease activity groups. Statistical analysis included descriptive statistics, linear correlation and regression and ROC curve.
RESULTS: A total of 227 patients with AS were included. ASDAS and BASDAI showed good correlation with disease activity as reflected by the patients' global score [r for BASDAI, ASDAS based on ESR(ASDAS-ESR) and ASDAS based on C-reactive protein (ASDAS-CRP) were 0.713, 0.698 and 0.725, respectively, P = 0.000] and the physician global score (r for BASDAI, ASDAS-ESR and ASDAS-CRP were 0.771, 0.782, 0.847, respectively, P = 0.000). Both scores showed good discriminative ability for high and low disease activity states. ASDAS-CRP had the highest sensitivity.
CONCLUSION: ASDAS is a promising tool for evaluating disease activity in AS patients.
METHODS: ASDAS and BASDAI were used to evaluate disease activity in patients with AS, taking the patients' global scores, physician global scores and treatment decision as the "gold standard" for disease activity. According to the "gold standard", the patients were divided into low and high disease activity groups. Statistical analysis included descriptive statistics, linear correlation and regression and ROC curve.
RESULTS: A total of 227 patients with AS were included. ASDAS and BASDAI showed good correlation with disease activity as reflected by the patients' global score [r for BASDAI, ASDAS based on ESR(ASDAS-ESR) and ASDAS based on C-reactive protein (ASDAS-CRP) were 0.713, 0.698 and 0.725, respectively, P = 0.000] and the physician global score (r for BASDAI, ASDAS-ESR and ASDAS-CRP were 0.771, 0.782, 0.847, respectively, P = 0.000). Both scores showed good discriminative ability for high and low disease activity states. ASDAS-CRP had the highest sensitivity.
CONCLUSION: ASDAS is a promising tool for evaluating disease activity in AS patients.